DAMASO OLIVA: Open Payments
NPI 1659304350 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$34,145 in 339 payments from 14 companies in 2025. Trend: 2023 $38,954 · 2024 $40,965 · 2025 $34,145
Consulting: $14,859Speaker / faculty: $10,738Food & beverage: $6,503Travel & lodging: $2,024Education: $22
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 51 | $15,775 |
| Neurocrine BioSciences, Inc. | 47 | $11,867 |
| E.R. Squibb & Sons, L.L.C. | 35 | $3,010 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 44 | $1,067 |
| Axsome Therapeutics, Inc. | 27 | $537 |
| Lundbeck LLC | 21 | $325 |
| Otsuka America Pharmaceutical, Inc. | 25 | $311 |
| Teva Pharmaceuticals USA, Inc. | 24 | $296 |
| ABBVIE INC. | 21 | $245 |
| Janssen Pharmaceuticals, Inc | 11 | $218 |
Products named: LYBALVI, INGREZZA, CAPLYTA, COBENFY, REXULTI, Auvelity, ARISTADA, VRAYLAR.
Industry payments across TX — which companies pay providers there.
